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➣  Intravenous Immune globulIn (IvIg), a fraction-
ated blood product extracted from pooled human plasma 
from blood donations, is given intravenously to treat pri-
mary immune deficiency diseases and a wide array of 
autoimmune diseases, infections and other conditions. 
For some conditions, IVIG has been shown to be effica-
cious in randomized controlled trials, but often the evi-
dence of benefit is less rigorous, with just case reports 
or uncontrolled case series suggesting benefit.
1–8 Many 
of  these  conditions  without  evidence  of  efficacy  are 
frequently treated with IVIG, which may not always be 
appropriate. Even in diseases where efficacy has been 
shown, appropriate use will depend on the stage and se-
verity of the condition and perhaps other factors.
Inappropriate use of IVIG exposes patients to un-
necessary risks from adverse reactions
9 and increases 
health care expenditures because of the high cost of 
IVIG. IVIG use in Canada more than quadrupled in the 
1990s,
10 and a typical course of IVIG (2 g/kg) for acute 
treatment currently costs more than Can$10  000. Also 
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ABSTRACT 
Background: Intravenous immune globulin (IVIG) is an expensive and sometimes scarce blood product that carries 
some risk. It may often be used inappropriately. We evaluated the appropriateness of IVIG use before and after the 
introduction of an utilization control program to reduce inappropriate use.
Methods: We used the RAND/UCLA Appropriateness Method to measure the appropriateness of IVIG use in the 
province of British Columbia (BC) in 2001 and 2003, before and after the introduction of a utilization control pro-
gram designed to reduce inappropriate use. For comparison, we measured the appropriateness of use during the same   
periods in the province of Alberta, which had no control program.
Results: Of 2256 instances of IVIG use, 54.1% were deemed to be appropriate, 17.4% were of uncertain benefit, and 
28.5% were deemed inappropriate. The frequency of inappropriate use in BC after the introduction of the utilization 
control program did not differ significantly from the frequency before the program or the frequency in Alberta.
Interpretation: Almost half of IVIG use in BC and Alberta was judged to be inappropriate or of uncertain benefit, and 
the frequency of inappropriate use did not decrease after implementation of a utilization control program in BC. More 
effective utilization controls are necessary to prevent wasted resources and unnecessary risk to patients.
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of concern is the marked regional disparity in IVIG use. 
In 2001/02, the province of British Columbia (BC) used 
0.07 g of IVIG per capita, whereas the province of Al-
berta used 0.12 g per capita.
11 Such marked variation 
suggests the possibility of either overuse (inappropriate 
use) or underuse.
12,13
Concerns about inappropriate use prompted BC to 
introduce the IVIG Management Program in 2002. This 
province-wide program involved the provision of a hand-
book on IVIG utilization management with guidelines for 
prescribers, and a more specific request form intended to 
reduce inappropriate use.
10 Alberta, in contrast, did not 
undertake any concerted program to manage IVIG use. 
We used this “natural experiment” to formally assess the 
appropriateness of IVIG use in BC and Alberta and the 
effectiveness of BC’s program. 
Methods
The protocol was approved by the University of Alberta 
Health Research Ethics Board. Appropriate ethics ap-
proval  and  permission  to  review  patient  charts  were 
obtained from each hospital and from individual phys-
icians, when necessary.  
Appropriateness ratings. We developed appropriate-
ness criteria using the RAND/UCLA Appropriateness 
Method, a process that has been widely used to assess 
the appropriateness of health care interventions.
13,14 This 
method uses the best published literature for the use of 
the “product” under study. Because this evidence is often 
incomplete and insufficient on its own to make informed 
therapeutic decisions, it is combined with expert clinical 
opinion to arrive at balanced appropriateness ratings 
for the various scenarios under which the intervention 
might be used.
We performed a comprehensive review of the litera-
ture, and analyzed and summarized the evidence for the 
efficacy and effectiveness of IVIG in all medical condi-
tions. We prepared a comprehensive set of clinical scen-
arios, each representing clinical circumstances under 
which IVIG might be used. The stage and severity of the 
diseases targeted by IVIG treatment were taken into ac-
count, as were other clinical factors that may influence 
treatment decisions. 
An expert panel comprising specialists nominated by 
various Canadian national specialty societies was then 
convened. It included an immunologist, two hematolo-
gists (adult and pediatric), a neuromuscular neurologist, 
an obstetrician, a rheumatologist, an infectious disease 
specialist, a transfusion expert, a dermatologist and a 
general  internist.  The  literature  review  and  complete 
list of scenarios were reviewed by the panel and then 
revised. The panelists individually rated each scenario, 
based on the evidence and their experience, on a 9-point 
scale, where 1–3 represented an inappropriate indica-
tion for IVIG, 4–6 an indication for which IVIG use was 
of uncertain benefit and 7–9 an appropriate indication. 
The panelists then met under the chairmanship of a gen-
eral internist/health services researcher (W.A.G.). Dur-
ing discussion of the scenarios, they made revisions and 
collapsed the initial set of 480 scenarios down to 326. 
Each scenario was then discussed and rated again, with 
no obligation for consensus. 
The median ratings for each scenario were then ap-
plied to cases during a review of patient charts to deter-
mine the level of appropriateness of IVIG use. Following 
the chart reviews, we noted that some cases (3.5% of in-
cident cases) did not correspond to any of the scenarios. 
We then developed 15 new scenarios to account for these 
cases, reviewed and summarized the relevant liberature 
and had the panel rate the new scenarios electonically. 
This left a total of 341 scenarios.
Cases and chart reviews.  All  patients  who  received 
IVIG in BC or Alberta in 2001 and 2003 were identified 
through lists kept by the BC Provincial Blood Coordinat-
ing Office and, in Alberta, by the blood banks of the indi-
vidual hospitals. Lists of hospitals using IVIG in Alberta 
outside  the  2  major  centres  (Calgary  and  Edmonton) 
were  obtained  from  the  Canadian  Blood  Services.  An 
electronic  chart  abstraction  database  was  constructed 
for the clinical data, incorporating all variables identified 
as necessary to categorize the cases by scenario, includ-
ing diagnosis and stage or severity of disease. Research 
assistants abstracting the clinical data were trained to 
review the patient charts and enter the data directly into 
the database using laptop computers. Information about 
demographics, complications, dates of initial and subse-
quent treatments, dose and duration of treatment were 
also collected. Information was collected from hospital 
and outpatient clinic charts and physicians’ office charts 
when necessary. Names and provincial health numbers 
were removed as soon as the full dataset was compiled. 
Appropriate privacy and security measures were taken, 
including full encryption of data.
Patient cases were divided into 2 categories on the 
basis of their clinical profiles: (1) incident cases (patients 
who received IVIG treatment for the first time in 2001 
or 2003); and (2) continuing chronic cases (patients who 
started treatment before 2001 or in 2002 and therefore 
were  not  considered  incident  cases  in  either  2001  or 
2003). For our study, we included only cases in the first Open Medicine 2012;6(1)e30
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category, because we focused our analysis on the appro-
priateness of new therapeutic decisions to give IVIG.
Analysis. Using the clinical information collected from 
the chart reviews, we rated the appropriateness of IVIG 
use in each case. A computerized algorithm mapped 
each of the cases to one of the previously rated scenarios. 
Each case was then assigned to one of the three appro-
priateness categories: “appropriate,” “inappropriate” and 
“uncertain.”
Data  analysis  and  presentation  were  primarily  de-
scriptive, with an overall reporting of the appropriateness 
of IVIG use, followed by a breakdown of appropriateness 
by main clinical indication (e.g., hematologic indications 
v. dermatologic v. immunologic v. other). Because the 
utilization control program was implemented in BC and 
not in Alberta, we performed a direct comparison of the 
appropriateness of IVIG use in the 2 provinces using the 
χ
2 test. In addition, we used logistic regression analysis 
to compare the appropriateness of IVIG use between the 
provinces while controlling for patient age, sex, clinical 
diagnosis and hospital teaching status.
To  ensure  a  high  level  of  interrater  reliability,  80 
charts were reviewed independently by both of the re-
search assistants performing the data abstraction and 
were assigned appropriateness ratings using the algo-
rithm as described above. The Kappa statistic for these 
dually reviewed charts was 0.65, which indicated sub-
stantial agreement.
15
Results
Categorization and rating of clinical scenarios. Of the 341 
unique scenarios covering the indications for which IVIG 
might be used, 77 (22.5%) were rated as appropriate (Table 
1). Details of the scenarios and their ratings 
are available in the Excel file “IVIG Scenarios 
and Rating,” available at www.imecchi.org/
IMECCHI/OurProjects.aspx). 
Description and rating of the clinical 
cases. In 2001 and 2003, there were 958 
incident cases of IVIG use in Alberta and 
1298 in BC, for corresponding rates of 34 
per 100 000 and 33 per 100 000 (we used 
Canadian census figures for the population 
of each province to create a mean popula-
tion base for each province for the 2 study 
years).
The cases from the two provinces were 
similar except that there were significantly 
more patients older than 65 years old in 
BC and fewer in teaching hospitals. There was a mod-
est increase in the number of cases in each province in 
2003  versus  2001.  The  most  common  indications  for 
IVIG use were in the diagnostic categories of hematology 
(32.2%),  neurology  (17.6%),  infectious  disease  (14.2%) 
and rheumatology (13.8%) (Table 2).
Overall, 54.1% of the cases were judged to be appro-
priate, 17.4% were of uncertain benefit and 28.5% were 
inappropriate  (Table  3).  The  highest  proportion  of  in-
appropriate cases was found in transplant care (80.8%), 
hematology (40.3%), obstetrics and gynecology (38.7%) 
and infectious diseases (24.6%). In the transplant cat-
egory, the leading scenario in which IVIG use was rated 
to be inappropriate was allogeneic bone marrow trans-
plant from a sibling donor. In hematology, it was initial 
treatment of idiopathic thrombocytopenic purpura in 
an adult with a platelet count of more than 20 × 109/L 
and no life-threatening bleeding. In obstetrics and gyne-
cology, the leading scenario was recurrent spontaneous 
abortion. In the category of infectious diseases, the lead-
ing scenario was prevention of infection in a patient with 
chronic lymphocytic leukemia who had low levels of IgG 
but no history of serious infection.
Comparison of appropriateness over time. In Alberta, 
47.3% of cases in 2001 and 43.6% in 2003 were judged to 
be appropriate (Table 4). In BC, the corresponding pro-
portions were 61.1% and 60.7%. There was no significant 
difference in appropriateness ratings over time in either 
province. In particular, the lack of improvement in BC 
between 2001 and 2003 indicates that the intervention, 
introduced in 2002, had no discernible early effect on 
the appropriateness of IVIG use.
Table 1:  Number of scenarios developed for assessing the appropriateness 
of intravenous immune globulin (IVIG) use appropriateness, inappropriateness 
and uncertainty
Diagnostic category
Rating of IVIG use;  no. of scenarios
Total  Appropriate Inappropriate Uncertain
Overall 77 136 128 341
Dermatology 5 19 20 44
Hematology 31 33 15 79
Infectious diseases 6 20 23 49
Neurology 21 18 30 69
Obstetrics / gynecology 2 5 2 9
Rheumatology 7 15 21 43
Transplantation 1 13 10 24
Immunology 4 0 1 5
Other 0 13 6 19Open Medicine 2012;6(1)e31
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Table 2:  Characteristics of new patients who received intravenous immune globulin
Characteristic
Alberta cases (N = 958)
n (%)
British Columbia cases (N = 1298)
n (%)  p value
Age, yr < 0.01
  ≤ 6 185 (19.3) 230 (17.7)
 7–17 119 (12.4) 93 (7.2)
 18–34 114 (11.9) 131 (10.1)
 35–64 343 (35.8) 494 (38.1)
  ≥ 65 197 (20.6) 350 (27.0)
Sex 0.46
 Female 439 (45.8) 615 (47.4)
 Male 519 (54.2) 683 (52.6)
Teaching hospital < 0.01
 No 127 (13.3) 645 (49.7)
 Yes 831 (86.7) 653 (50.3)
Diagnostic category < 0.01
 Dermatology 21 (2.2) 23 (1.8)
 Hematology 288 (30.1) 441 (34.0)
  Infectious diseases 120 (12.5) 201 (15.5)
 Neurology 165 (17.2) 233 (18.0)
  Obstetrics / gynecology 16 (1.7) 15 (1.2)
 Rheumatology 123 (12.8) 189 (14.6)
 Transplantation 129 (13.5) 53 (4.1)
 Immunology 39 (4.1) 91 (7.0)
 Miscellaneous 14 (1.5) 10 (0.8)
 Missing 43 (4.5) 42 (3.2)
Year 0.63
 2001 467 (48.7) 646 (49.8)
 2003 491 (51.3) 652 (50.2)
Table 3:  Appropriateness of intravenous immune globulin use in new patients, by diagnostic category
Diagnostic category Cases, n
Rating of IVIG use;  no. (%) of all cases Inappropriate use by province; n (%) of cases
p value Appropriate Inappropriate Uncertain Alberta British Columbia
Overall 2256 1221 (54) 642 (29) 393 (17) 343 299 0.006
Dermatology 44 8 (18) 0 36 (82)  0 0 –
Hematology 729 397 (55) 294 (40) 38 (5) 144 (42) 150 (50) 0.038
Infectious diseases 321 113 (35) 79 (25) 129 (40) 33 (10) 46 (15) 0.027
Neurology 398 304 (76) 29 (7) 65 (16) 16 (5) 13 (4) 0.847
Obstetrics / gynecology 31 10 (32) 12 (39) 9 (29) 8 (2) 4 (1) 0.353
Rheumatology 312 261 (84) 15 (5) 36 (12) 6 (2) 9 (3) 0.292
Transplantation 182 10 (6) 147 (81) 25 (14) 98 (29) 49 (16) 0.001
Immunology 130 115 (89) 0 15 (12) 0 0 –
Miscellaneous 24 3 (13) 7 (29) 14 (58) 5 (1) 2 (1) 0.347
Missing 85 0 59 (69) 26 (31) 33 (10) 26 (9) 0.686Open Medicine 2012;6(1)e32
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Discussion
We found that the frequency of inappropriate and uncer-
tain use of IVIG was surprisingly high in Alberta and BC. 
The  frequency  of  inappropriate  use  did  not  decrease 
significantly in BC after the introduction of the formal 
program of utilization controls, nor was it significantly 
lower than the frequency in Alberta, where there were no 
utilization controls. 
This  is  not  the  first  study  to  assess  the  pattern  of 
IVIG use, its general appropriateness or the indications 
for use. Hanna and colleagues
16 described the pattern 
of IVIG use across Canada and the indications for use. 
They reported indications for use that were similar to 
those we have described. Their findings hint at a lack of 
uniform appropriateness, although they did not assess 
appropriateness using a formal method such as the one 
we used. Similarly, Lin and colleagues
17 and Hutchison 
and colleagues
18 assessed the use of IVIG in Australia 
and New Zealand, respectively. They found considerable 
interregional variation in utilization (this is typically a 
flag for both under- and over-utilization across jurisdic-
tions
12,13), and some questionable indications for use.
Our study extends these findings by using the more 
formal RAND/UCLA Appropriateness Method to study 
the appropriateness of IVIG use. That almost half of the 
cases of IVIG use were judged to be either inappropriate 
or of uncertain benefit is cause for concern. IVIG is an 
expensive and at times scarce blood product that confers 
substantial risk on its recipients.
9 Steps should be taken 
to reduce inappropriate use. As a first step, our methodo-
logic template and scenarios can be applied by other juris-
dictions interested in assessing IVIG use, and for this, 
the scenarios that we publish on the IMECCHI (Inter-
national Methodology Consortium for Coded Health In-
formation) website (www.imecchi.
org/IMECCHI/OurProjects.aspx)
constitute a methodologic tool for 
similar studies aimed at improv-
ing appropriateness.
Our  findings  raise  ques-
tions  about  why  BC’s  utiliza-
tion control program failed to 
reduce inappropriate IVIG use.   
It is not surprising that the hand-
book and guidelines on IVIG use 
may not have influenced prescrib-
ing behaviour, given the abundant 
literature  showing  that  clinical 
practice guidelines do not consist-
ently change phyisician behav-
iour.
19,20  However,  the  apparent 
lack of effect of the special request form designed to re-
duce inappropriate orders for IVIG is surprising. A pos-
sible contributing factor to the program’s lack of impact 
was that the baseline pattern of IVIG use in the province 
was already judged to be reasonably appropriate, but this 
alone does not fully explain the lack of effect. The per-
sistence of inappropriate use of IVIG after implementa-
tion of the special request form suggests that orders for 
IVIG use in situations where use was inappropriate were 
not being blocked (otherwise, one would expect to have 
seen a precipitous drop in inappropriate IVIG use). Fur-
ther, the form and the related utilization control program 
may have permitted some questionable use to proceed, 
because it may not have aligned fully with the indications 
that the RAND/UCLA Appropriateness Method identified 
as inappropriate. 
Utilization controls in other clinical areas have had 
some positive effects. For example, Samore and col-
leagues
21 used a utilization control program that reduced 
inappropriate use of antibiotics in community practice 
settings. Bertakis and colleagues
22 developed a program 
that successfully targeted patients through education to 
reduce inappropriate use of health services. Constantine 
and colleagues
23 described a program in Atlantic Canada 
that may have slightly reduced the frequency of inappro-
priate use of IVIG; however, the evaluation of its effects 
was limited in its scope, and inappropriate use remained 
quite rampant despite the program’s implementation in 
the mid-2000s. Targeted educational interventions can 
also have some effect in reducing inappropriate use, as 
has been shown in peri-surgical blood transfusion.
24
Effective reduction of inappropriate IVIG use will re-
quire the development of more formal and vigorous util-
ization controls, with targeted educational interventions. 
Table 4:  Appropriateness of intravenous immune globulin use in new patients, 
by intervention group
Intervention group; rating of IVIG use
Year 2001* 
n (%)
Year 2003† 
n (%)
p value for appropriateness
(year 2001 versus 2003)
Crude Risk-adjusted‡
Alberta (non-intervention province)
Appropriate 221 (47.3) 214 (43.6) 0.93 0.70
Inappropriate 163 (34.9) 180 (36.7)
Uncertain 83 (17.8) 97 (19.8)
British Columbia (intervention province)
Appropriate 392 (61.1) 394 (60.7) 0.42 0.31
Inappropriate 141 (22.0) 158 (24.3)
Uncertain 113 (17.6) 100 (15.4)
* Before intervention
† After intervention
‡ Adjusted for age, sex, teaching hospital and diagnosis category. (Adjusted and unadjusted p values < 0.01 for 
comparison of appropriate use between non-intervention and intervention group.)Open Medicine 2012;6(1)e33
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Formal evaluation of the control program after its imple-
mentation will be required to ensure that it is reducing 
inappropriate use. The tools that we have developed for 
this study could be used for future evaluations of IVIG 
appropriateness in other jurisdictions.
Limitations. Our study has limitations. Most notably, 
our evaluation of the utilization control program in BC 
was merely an observational before–after study. The in-
clusion of IVIG use in Alberta for comparison strength-
ened the evaluation, but this approach still fell short of 
the inferences that could be drawn from a more defin-
itive evaluation design such as a cluster randomized trial 
of utilization controls. Second, some years have passed 
since implementation of the program in BC. We inten-
tionally focused our assessment around the years of the 
program’s implementation, but there is now a clear need 
for continued assessment of IVIG use in more recent 
years. Third, our findings do not explain why the pro-
gram had no effect. Physician interviews or surveys are 
one method that could be used to explore the underlying 
reasons. Fourth, we did not examine outcomes. We thus 
do not have evidence of ineffectiveness or harm in cases 
of inappropriate use, although this may be inferred. 
Finally, our appropriateness ratings were based in part 
on a comprehensive review of the IVIG literature rather 
than on a more rigorous systematic review.
Summary 
Almost half of the instances of IVIG use in BC and Al-
berta were judged to be inappropriate or of uncertain 
benefit and that the frequency of inappropriate use did 
not decrease after implementation of a utilization con-
trol program in BC. These findings indicate that the use 
of this expensive product of limited availability requires 
continued monitoring through repeated appropriateness 
evaluations, and that jurisdictions need to consider the 
implementation and evaluation of more vigorous utiliza-
tion control programs.
More broadly, high levels of inappropriate use have 
been found for many therapeutic and diagnostic health 
care interventions in many jurisdictions.
25 Reduction of 
inappropriate use could improve health outcomes, re-
duce health care costs and improve access to care. This 
would require the systematic study of appropriateness 
across a wide array of health care interventions coupled 
with the prospective implementation of appropriateness-
informed utilization controls.
25
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